Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Strong operating and pipeline evidence: Q2 2026 net product revenue rose about 55% YoY to $243.6M, management raised 2026 revenue guidance to $980M-$995M, and positive KPL-387 Phase 2 data supports the pipeline. The stock is up about 25% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Position ⢠High Gross Margins ⢠Rising Valuation KNSA has strong liquidity, low debt, high margins and solid cash generation, but elevated operating costs, negative retained earnings, dilution, and sharply higher valuation multiples warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Range-bound trading ⢠Resistance rejection ⢠Weakening momentum Support Level: $78.00; stronger support $76.10â$76.80 Resistance Level: $80.20â$80.80 KNSA is mildly constructive but range-bound over the last month, with $78.00 support (then $76.10â$76.80) and $80.20â$80.80 resistance; a close above $80.80 is bullish, while a break below $78.00 risks a deeper pullback after the sharp drop from $80.47.
Sentiment & News
Key News Insights: ⢠ARCALYST Growth ⢠Phase 3 Progress ⢠Pipeline Momentum Kiniksa's ARCALYST growth and KPL-387 Phase 3 advancement reinforce positive commercial and pipeline momentum.
AI Summary
Kiniksa is now a profitable, cash-generative specialty-pharma company anchored by ARCALYST's near-$1B revenue trajectory, but at a rich valuation investors should own it only if they expect sustained commercial outperformance and view KPL-387 as upside rather than certainty. The key risk is ARCALYST concentration: any growth or guidance slowdown could trigger sharp multiple compression.
Description
Kiniksa Pharmaceuticals is a biopharmaceutical company that discovers, acquires, develops and commercializes therapies for patients with serious conditions lacking adequate treatment options. Its portfolio includes an approved interleukin-1 therapy for recurrent pericarditis and several monoclonal antibody candidates in clinical development for inflammatory and immune-mediated diseases. The company was incorporated in 2015 and is headquartered in Hamilton, Bermuda.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 30 | Aug 6 | KNSA | Kiniksa Pharmaceuticals, Ltd. | Strong operating and pipeline evidence: Q2 2026 net product revenue rose about 55% YoY to $243.6M, management raised 2026 revenue guidance to $980M-$995M, and positive KPL-387 Phase 2 data supports the pipeline. The stock is up about 25% over 21 trading days. | Closed | -2.2% |
| Apr 29 | May 6 | KNSA | Kiniksa Pharmaceuticals, Ltd. | Q1 2026 beat expectations with EPS of $0.27 vs. $0.18 expected, ARCALYST revenue rose 56% YoY to $214.3M, 2026 ARCALYST revenue guidance was raised to $930M-$945M, and the stock is trading near 52-week highs. | Closed | +9.9% |